A phase 2 study of ALKS 2680 in patients with Idiopathic-hypersomnia.
Latest Information Update: 28 Oct 2024
At a glance
- Drugs ALKS 2680 (Primary)
- Indications Idiopathic hypersomnia
- Focus Therapeutic Use
- 28 Oct 2024 According to Alkermes plc Media release, company also announced its plans to initiate a phase 2 study in patients with IH in 2025.
- 28 Oct 2024 New trial record